Guardant Health, Inc. (GH)

Guardant Health, Inc. is a leading precision oncology company that focuses on developing blood tests for cancer detection, treatment, and recurrence monitoring. Founded in 2012 by Helmy Eltoukhy and AmirAli Talasaz, the company aims to revolutionize cancer diagnostics through non-invasive methods. As of 2023, Helmy Eltoukhy serves as the CEO. Guardant Health is renowned for its flagship product, the Guardant360 liquid biopsy, which helps identify mutations in tumors and guide treatment decisions. The company has earned recognition for its innovative approach to cancer care and is committed to expanding its offerings to include early cancer detection. Publicly traded under the ticker symbol “GH,” Guardant Health reported revenues of approximately $373 million in 2022. With a strong emphasis on research and development, the company collaborates with numerous healthcare institutions and pharmaceutical companies to advance the use of precision medicine in oncology.